Dutasteride in the treatment of benign prostatic hyperplasia: an update.
- Author:
Hong-jie CHEN
1
;
Yi-rong CHEN
Author Information
1. Department of Urology, The First Renmin Hospital of Lanzhou, Lanzhou, Gansu 730050, China.
- Publication Type:Journal Article
- MeSH:
5-alpha Reductase Inhibitors;
therapeutic use;
Azasteroids;
therapeutic use;
Dutasteride;
Humans;
Male;
Prostatic Hyperplasia;
drug therapy
- From:
National Journal of Andrology
2011;17(1):63-67
- CountryChina
- Language:Chinese
-
Abstract:
Benign prostatic hyperplasia (BPH) is a common disease in older men. At present, 5alpha reductase inhibitor-based medication, preferred by most BPH patients as the first-choice therapy, is taking place of traditional transurethral resection of the prostate. This article presents an update of the researches on the treatment of BPH with dutasteride--a novel 5 alpha-reductase inhibitor.
